JAN 23, 2018 02:43 PM PST

Unique Epigenetic Signatures Diagnose Rare Disorders

WRITTEN BY: Kara Marker
4 6 334

Epigenetic changes impact gene activity without actually altering the sequence of DNA, and scientists are now able to diagnose rare disorders based on specific epigenetic signatures. From the Greenwood Genetic Center (GGC), scientists are improving diagnosis of neurodevelopmental disorders that are often difficult to tell apart.

DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer. Credit: Christoph Bock, Max Planck Institute for Informatics

"Many of the disorders we studied have clinical overlap, which makes sense as the genes causing each of these disorders all work within the same epigenetic machinery, determining the gene's expression and expression of other genes," explained co-author Charles Schwartz, PhD.

But in a new study of 14 neurodevelopmental disorders, Schwartz and other GGC researchers identified nine of the disorders as having unique methylation signatures. DNA methylation is a known process of epigenetics, where a methyl group is either added or removed to change DNA expression. The research team was able to produce this finding using a methylation array analysis. Of the rare disorders included in this study, Sotos syndrome, Kabuki syndrome, CHARGE syndrome, and ATRX were among those with unique epigenetic signatures.

Applying each of the signatures associated with the disorders to existing tests could greatly improve the accuracy of diagnoses. Scientists could screen for multiple symptoms with maximum sensitivity and specificity. Additionally, they could build a “single machine learning classification tool” to make accurate diagnoses.

Most important is using the unique epigenetic sequences to differentiate between each of the nine disorders. For patients whose results show no sign of any of the nine disorders, researchers could also assign “low probability scores,” providing the patients additional information of their risk of developing these disorders.

Lastly, facilitating these tests could be faster and more efficient, with no need for parental samples or brain tissue to test; peripheral blood samples from each patient will suffice.

Schwartz says that the findings also produced an “epigenetic echo model” that illustrates additional information about each disorder’s unique epigenetic signature: what causes them to develop and cause disease.

"The echo model states that while an initial epigenetic dysfunction arises during early development, a broader methylation legacy or echo remains throughout the genome leading to the unique signature,” Schwartz explained. “This may help explain the variability and phenotypic overlap among these disorders."

The present study was published in the journal American Journal of Human Genetics.

Sources: Environmental Health Perspectives, Greenwood Genetic Center

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 28, 2018
Cardiology
MAR 28, 2018
Printed Tattoo Electrodes Transmit Human Heart Impulses
Diagnostic electrodes for measuring electrical impulses from the heart and muscles are uncomfortable for patients and dry out quickly. So scientists from t
APR 12, 2018
Cardiology
APR 12, 2018
Menopause Symptoms Associated with Poor Vascular Health
For the first time, scientists are researching the link between mood, menopausal symptoms, quality of life, and vascular health. From the University of Col
APR 23, 2018
Cancer
APR 23, 2018
UroSEEK: Early Bladder and Urothelial Cancer Urine Screening Test Developed to Complement Urine Cytology
New, non-invasive urine screening test called UroSEEK was developed by Johns Hopkins to detect low grade bladder and urothelial cancers using DNA detection methods and technology.
MAY 14, 2018
Cancer
MAY 14, 2018
What Is Computational Oncology?
Computational Oncology is an emerging field of science and medicine aimed at using mathematical and computer modeling systems to organize tumor marker profiles and hone precision medicine.
JUN 07, 2018
Clinical & Molecular DX
JUN 07, 2018
Digital Screening Vital for Detecting Breast Cancer
A combination of two digital techniques could be the best way to diagnose breast cancer. In a new study, scientists show how combining a technique called t
JUL 13, 2018
Genetics & Genomics
JUL 13, 2018
Detecting Leukemia Before it Starts Growing
Researchers have found ways to identify people who may develop an aggressive type of blood cancer while they are still healthy.
Loading Comments...